Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases including NASH, withdrew its plans for an initial public offering on Tuesday. It originally filed in April 2014 with a proposed deal size of $75 million. In May 2014, it agreed to be bought by the Irish pharmaceutical company Shire (NASDAQ: SHPG) for $260 million plus milestone...read more
Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol LIVR. Lumena Pharmaceuticals initially filed confidentially on February 28, 2014. Citi,...read more
Biotech Lumena Pharmaceuticals officially withdraws $75 million IPO; acquired by Shire in 2014
Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases including NASH, withdrew its plans for an initial public offering on Tuesday. It originally filed in April 2014 with a proposed deal size of $75 million. In May 2014, it agreed to be bought by the Irish pharmaceutical company Shire (NASDAQ: SHPG) for $260 million plus milestone...read more
Liver disease biotech Lumena Pharmaceuticals files for a $75 million IPO
Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol LIVR. Lumena Pharmaceuticals initially filed confidentially on February 28, 2014. Citi,...read more